Photo of David Claxton
Contact Expert

View Scopus Profile

David Claxton, MD

 https://orcid.org/0000-0001-9209-2405
    • 8225 Citations
    • 39 h-Index
    1989 …2019
    If you made any changes in Pure, your changes will be visible here soon.

    Personal profile

    Research interests

    Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

    Fingerprint Dive into the research topics where David Claxton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 19 Similar Profiles
    Acute Myeloid Leukemia Medicine & Life Sciences
    Leukemia Medicine & Life Sciences
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
    Bone Marrow Medicine & Life Sciences
    Therapeutics Medicine & Life Sciences
    Neoplasms Medicine & Life Sciences
    Hematologic Neoplasms Medicine & Life Sciences
    Stem Cells Medicine & Life Sciences

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Projects 1989 2019

    Targeted Sphingolipid Metabolism for Treatment of AML

    Claxton, D., Wang, H., Wang, H., Amin, S., Liao, J. (., Fox, T., Loughran, T. P., Loughran, T. P., Kester, M., Kester, M. & Cabot, M. C.

    National Institutes of Health

    9/10/13 → 8/31/19

    Project: Research project

    Acute Myeloid Leukemia
    Acid Ceramidase
    Sphingolipids
    Ceramides
    Tamoxifen

    THERAPY OF AML

    Claxton, D., Deisseroth, A., Siciliano, M., Benedict, W., Reading, C., Liang, J., Plunkett, W., Thall, P., Thomas, M., Reed, J., Andreeff, M., Berry, D., Kornblau, S., Croce, C., Estey, E., Nagarajan, L., Deisseroth, A. & Champlin, R. E.

    National Institutes of Health

    6/1/92 → 8/31/15

    Project: Research project

    Core Binding Factors
    Genes
    Transcription Factors
    Leukemia
    Genetically Modified Animals

    THERAPY OF CML

    Claxton, D., Kurzrock, R., Ming-Sheng, L., Reading, C., Emerson, S., Liang, J., Feinberg, A., Deisseroth, A., Siciliano, M., Kantarjian, H., Talpaz, M., Andreeff, M., Kornblau, S., Thall, P., Issa, J., Estrov, Z., Arlinghaus, R. B., Deininger, M., Shpall, E., Champlin, R., Belmont, J., Reisner, Y., Austin, D., Issa, K. & Cortés, J.

    National Institutes of Health

    12/1/89 → 6/30/16

    Project: Research project

    Dendritic Cells
    Immunity
    Lymphocytes
    Cytogenetics
    Therapeutics

    Research Output 1989 2019

    1 Citation (Scopus)

    Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation

    Tan, S. F., Dunton, W., Liu, X., Fox, T. E., Morad, S. A. F., Desai, D., Doi, K., Conaway, M. R., Amin, S., Claxton, D., Wang, H. G., Kester, M., Cabot, M. C., Feith, D. J. & Loughran, T. P., Jan 1 2019, In : Journal of Lipid Research. 60, 6, p. 1078-1086 9 p.

    Research output: Contribution to journal › Article

    Acid Ceramidase
    P-Glycoprotein
    Drug Resistance
    Acute Myeloid Leukemia
    Up-Regulation
    10 Citations (Scopus)

    A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403

    Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., Paietta, E., Parker, E., Geyer, S., Mrózek, K., Bloomfield, C. D., Sanford, B., Marcucci, G., Liedtke, M., Claxton, D., Foster, M. C. & 8 others, Bogart, J. A., Grecula, J. C., Appelbaum, F. R., Erba, H., Litzow, M. R., Tallman, M. S., Stone, R. M. & Larson, R. A., Apr 4 2019, In : Blood. 133, 14, p. 1548-1559 12 p.

    Research output: Contribution to journal › Article

    Pediatrics
    Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Young Adult
    Confidence Intervals
    Disease-Free Survival

    Downregulation of CD73 associates with T cell exhaustion in AML patients

    Kong, Y., Jia, B., Zhao, C., Claxton, D., Sharma, A., Annageldiyev, C., Fotos, J., Zeng, H., Paulson, R., Prabhu, K. S. & Zheng, H., Apr 24 2019, In : Journal of Hematology and Oncology. 12, 1, 40.

    Research output: Contribution to journal › Article

    Open Access
    Acute Myeloid Leukemia
    Down-Regulation
    T-Lymphocytes
    Adenosine
    Neoplasms
    1 Citation (Scopus)

    Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia

    Jia, B., Zhao, C., Rakszawski, K. L., Claxton, D., Ehmann, W. C., Rybka, W., Mineishi, S., Wang, M., Shike, H., Bayerl, M., Sivik, J. M., Schell, T., Drabick, J., Hohl, R. & Zheng, H., Apr 1 2019, In : Cancer Research. 79, 7, p. 1635-1645 11 p.

    Research output: Contribution to journal › Article

    Open Access
    Acute Myeloid Leukemia
    T-Lymphocytes
    Leukemia
    Transcription Factors
    Induction Chemotherapy

    Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study

    Pu, J. J., Poulose, J., Malysz, J., Zhu, J., Fanburg-Smith, J., Claxton, D. & Bayerl, M., Jan 1 2019, In : British Journal of Haematology. 186, 5, p. e130-e133

    Research output: Contribution to journal › Letter

    Open Access
    Primary Myelofibrosis
    Stem Cells
    Transplants
    INCB018424